Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE OK For BMS's Opdivo To Shake Up UK RCC Market, Bad News For Pfizer

Executive Summary

Bristol-Myers Squibb's Opdivo looks set to blow rivals out the water in renal cell carcinoma as NICE U-turns on negative recommendation, just weeks after the company revealed the full extent of the drug’s disappointment in first-line lung cancer.

Advertisement

Related Content

NICE Move On Cabometyx Gives BMS Longer To Make Opdivo Case In Second Line RCC
NICE Rejects BMS' Opdivo As Adult Kidney Cancer Treatment

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097513

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel